Abstract
Objective: Significant reductions in perinatal human immunodeficiency virus (HIV) transmission have been demonstrated in which the HIV-infected mothers and their HIV-exposed infants receive prenatal, intrapartum, and neonatal antiretroviral therapy. Study Design: We used data that were collected through the Enhanced Perinatal Surveillance system for HIV-exposed singleton births that occurred 1999-2001 in 24 sites. Results: The overall infant infection rate for the 3 years was 4.7%. Compared with zidovudine monotherapy, those patients who received zidovudine with other drugs that included a protease inhibitor and those who received zidovudine and other drugs with no protease inhibitor were less likely to have an infected infant (adjusted odds ratio, 0.4 [95% CI, 0.3-0.07]; adjusted odds ratio, 0.5 [95% CI, 0.3-0.8], respectively). Conclusion: These data support the current treatment recommendations and show that infants were less likely to be infected when the mothers were given a prenatal antiretroviral therapy regimen that contained zidovudine with additional antiretroviral drugs with or without a protease inhibitor in addition to receiving antiretrovirals during delivery and neonatally.
Original language | English (US) |
---|---|
Pages (from-to) | S33-S41 |
Journal | American journal of obstetrics and gynecology |
Volume | 197 |
Issue number | 3 SUPPL. |
DOIs | |
State | Published - Sep 2007 |
Externally published | Yes |
Keywords
- HIV/AIDS
- antiretroviral
- perinatal
- surveillance
ASJC Scopus subject areas
- Obstetrics and Gynecology